NFKB1 and diffuse large B-cell lymphoma: TCF3 was noted to upregulate components of the B-cell receptor (BCR) pathway leading to activation of the phosphatidylinositol-3-kinase (PI3K) pathway through “tonic” non-NF-kB dependent BCR signaling, rather than the NF-kB dependent chronic active BCR signaling seen in activated B-cell like (ABC) DLBCL, potentially through its effects on the phosphatase SHP-1 which inhibits BCR signaling.